Jianfa Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3638391/publications.pdf

Version: 2024-02-01

		186265	233421
75	2,384	28	45
papers	citations	h-index	g-index

76	76	76	3181
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nature Communications, 2014, 5, 5393.	12.8	180
2	Directing cellular information flow via CRISPR signal conductors. Nature Methods, 2016, 13, 938-944.	19.0	149
3	Engineering cell signaling using tunable CRISPRâ€“Cpf1-based transcription factors. Nature Communications, 2017, 8, 2095.	12.8	101
4	Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Letters, 2016, 376, 155-164.	7.2	84
5	LncRNA MALAT1 Inhibits Apoptosis and Promotes Invasion by Antagonizing miR-125b in Bladder Cancer Cells. Journal of Cancer, 2017, 8, 3803-3811.	2.5	79
6	Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. IScience, 2020, 23, 101411.	4.1	75
7	Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 83.	8.6	71
8	Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 99.	8.6	70
9	Over-expression of long noncoding RNA BANCR inhibits malignant phenotypes of human bladder cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 125.	8.6	64
10	Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. International Journal of Medical Sciences, 2018, 15, 645-652.	2.5	60
11	shRNA targeting long non-coding RNA CCAT2 controlled by tetracycline-inducible system inhibits progression of bladder cancer cells. Oncotarget, 2016, 7, 28989-28997.	1.8	60
12	AFAP1â€AS1: A novel oncogenic long nonâ€coding RNA in human cancers. Cell Proliferation, 2018, 51, .	5.3	57
13	Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Oncotarget, 2016, 7, 16038-16048.	1.8	50
14	Inducing cell growth arrest and apoptosis by silencing long non-coding RNA PCAT-1 in human bladder cancer. Tumor Biology, 2015, 36, 7685-7689.	1.8	49
15	Enhancer RNAs (eRNAs): New Insights into Gene Transcription and Disease Treatment. Journal of Cancer, 2018, 9, 2334-2340.	2.5	49
16	The Function and Mechanism of Long Non-coding RNA-ATB in Cancers. Frontiers in Physiology, 2018, 9, 321.	2.8	48
17	Decreased expression of LncRNA MIR31HG in human bladder cancer. Cancer Biomarkers, 2016, 17, 231-236.	1.7	44
18	Long nonâ€coding PANDAR as a novel biomarker in human cancer: A systematic review. Cell Proliferation, 2018, 51, .	5.3	44

#	Article	IF	Citations
19	Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells. Scientific Reports, 2016, 6, 30798.	3.3	40
20	Long non-coding RNA CRNDE in cancer prognosis: Review and meta-analysis. Clinica Chimica Acta, 2018, 485, 262-271.	1.1	38
21	Increased expression of ZEB1-AS1 correlates with higher histopathological grade and promotes tumorigenesis in bladder cancer. Oncotarget, 2017, 8, 24202-24212.	1.8	37
22	Circular RNA MYLK promotes tumour growth and metastasis via modulating miRâ€513aâ€5p/VEGFC signalling in renal cell carcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 6609-6621.	3.6	35
23	SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers. Tumor Biology, 2017, 39, 101042831771140.	1.8	34
24	A CRISPR-Cas12a-based specific enhancer for more sensitive detection of SARS-CoV-2 infection. EBioMedicine, 2020, 61, 103036.	6.1	34
25	Role of long noncoding RNA UCA1 as a common molecular marker for lymph node metastasis and prognosis in various cancers: a meta-analysis. Oncotarget, 2017, 8, 1937-1943.	1.8	33
26	Colon cancer associated transcripts in human cancers. Biomedicine and Pharmacotherapy, 2017, 94, 531-540.	5.6	32
27	A Multifunction Lipid-Based CRISPR-Cas13a Genetic Circuit Delivery System for Bladder Cancer Gene Therapy. ACS Synthetic Biology, 2020, 9, 343-355.	3.8	31
28	Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/Î²-catenin signaling pathway in bladder cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 136.	8.6	31
29	Organoid Cultures Derived From Patients With Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1410-1426.	3.6	30
30	Dendritic cells in semen of infertile men: association with sperm quality and inflammatory status of the epididymis. Fertility and Sterility, 2014, 101, 70-77.e3.	1.0	26
31	Synthetic artificial microRNAs targeting UCA1-MALAT1 or c-Myc inhibit malignant phenotypes of bladder cancer cells T24 and 5637. Molecular BioSystems, 2015, 11, 1285-1289.	2.9	26
32	An Efficient Light-Inducible P53 Expression System for Inhibiting Proliferation of Bladder Cancer Cell. International Journal of Biological Sciences, 2016, 12, 1273-1278.	6.4	26
33	Long noncoding RNA HOTTIP as a novel predictor of lymph node metastasis and survival in human cancer: a systematic review and meta-analysis. Oncotarget, 2017, 8, 14126-14132.	1.8	26
34	Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells. Nature Communications, 2020, 11, 5486.	12.8	25
35	Synthesizing a Genetic Sensor Based on CRISPR-Cas9 for Specifically Killing p53-Deficient Cancer Cells. ACS Synthetic Biology, 2018, 7, 1798-1807.	3.8	24
36	Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer. International Journal of Biological Sciences, 2018, 14, 1268-1276.	6.4	23

#	Article	IF	Citations
37	BANCR: a novel oncogenic long non-coding RNA in human cancers. Oncotarget, 2017, 8, 94997-95004.	1.8	22
38	Roles of ER<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mo mathvariant="bold">Î²</mml:mo></mml:mrow></mml:math>and GPR30 in Proliferative Response of Human Bladder Cancer Cell to Estrogen. BioMed Research International, 2015, 2015, 1-10.	1.9	21
39	YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma. Frontiers in Pharmacology, 2021, 12, 709548.	3.5	21
40	Targeting cellular mRNAs translation by CRISPR-Cas9. Scientific Reports, 2016, 6, 29652.	3.3	19
41	Long noncoding RNA CCAT2 as a novel biomaker of metastasis and prognosis in human cancer: a meta-analysis. Oncotarget, 2017, 8, 75664-75674.	1.8	19
42	Engineering mannosylated pickering emulsions for the targeted delivery of multicomponent vaccines. Biomaterials, 2022, 280, 121313.	11.4	18
43	A Novel Mutation of DAX-1 Associated with Secretory Azoospermia. PLoS ONE, 2015, 10, e0133997.	2.5	17
44	Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 3.	8.6	17
45	Multiplexed promoterless gene expression with CRISPReader. Genome Biology, 2019, 20, 113.	8.8	17
46	Synthetic Tet-inducible artificial microRNAs targeting Î²-catenin or HIF-1Î± inhibit malignant phenotypes of bladder cancer cells T24 and 5637. Scientific Reports, 2015, 5, 16177.	3.3	16
47	Oestrogen promotes tumorigenesis of bladder cancer by inducing the enhancer RNAâ€"eGREB1. Journal of Cellular and Molecular Medicine, 2018, 22, 5919-5927.	3.6	15
48	LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase expression. Bioscience Reports, 2019, 39, .	2.4	15
49	Long noncoding RNA MALAT1 acts as a potential biomarker in cancer diagnosis and detection: a meta-analysis. Biomarkers in Medicine, 2019, 13, 45-54.	1.4	15
50	Synthesizing artificial devices that redirect cellular information at will. ELife, 2018, 7, .	6.0	14
51	Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells. Molecular BioSystems, 2017, 13, 1597-1607.	2.9	12
52	Knockdown of long noncoding RNA FGFR3- AS1 induces cell proliferation inhibition, apoptosis and motility reduction in bladder cancer. Cancer Biomarkers, 2018, 21, 277-285.	1.7	11
53	Current Advances on the Important Roles of Enhancer RNAs in Gene Regulation and Cancer. BioMed Research International, 2018, 2018, 1-6.	1.9	10
54	Improving transgene expression and CRISPRâ€Cas9 efficiency with molecular engineeringâ€based molecules. Clinical and Translational Medicine, 2020, 10, e194.	4.0	10

#	Article	IF	Citations
55	RNAi-mediated control of CRISPR functions. Theranostics, 2020, 10, 6661-6673.	10.0	10
56	Synthesizing oncogenic signal-processing systems that function as both â€œsignal countersâ€•and â€œsignal blockersâ€•in cancer cells. Molecular BioSystems, 2013, 9, 1909.	2.9	9
57	Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells. Tumor Biology, 2016, 37, 3115-3121.	1.8	9
58	Recent development on synthetic biological devices treating bladder cancer. Synthetic and Systems Biotechnology, 2016, 1, 216-220.	3.7	8
59	Identification of differentially expressed circular RNAs in human nasopharyngeal carcinoma. Cancer Biomarkers, 2020, 29, 483-492.	1.7	8
60	High expression of enhancer RNA MARC1 or its activation by DHT is associated with the malignant behavior in bladder cancer. Experimental Cell Research, 2018, 370, 303-311.	2.6	7
61	A revolutionary tool: CRISPR technology plays an important role in construction of intelligentized gene circuits. Cell Proliferation, 2019, 52, e12552.	5.3	7
62	Inhibiting cell migration and cell invasion by silencing the transcription factor ETS-1 in human bladder cancer. Oncotarget, 2016, 7, 25125-25134.	1.8	7
63	Synthetic artificial "long non-coding RNAs" targeting oncogenic microRNAs and transcriptional factors inhibit malignant phenotypes of bladder cancer cells. Cancer Letters, 2018, 422, 94-106.	7.2	6
64	A synthetic targeted RNA demethylation system based on CRISPRâ€Cas13b inhibits bladder cancer progression. Clinical and Translational Medicine, 2022, 12, e734.	4.0	5
65	Protein corona-driven nanovaccines improve antigen intracellular release and immunotherapy efficacy. Journal of Controlled Release, 2022, 345, 601-609.	9.9	5
66	Lentivirus-mediated shRNA targeting MUTYH inhibits malignant phenotypes of bladder cancer SW780 cells. OncoTargets and Therapy, 2018, Volume 11, 6101-6109.	2.0	4
67	A CRISPR/dCasXâ€mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing câ€MYC or activating TP53. Clinical and Translational Medicine, 2021, 11, e537.	4.0	4
68	Synthesis of RNA-based gene regulatory devices for redirecting cellular signaling events mediated by p53. Theranostics, 2021, 11, 4688-4698.	10.0	2
69	Role of nuclear paraspeckle assembly transcript 1 as a common molecular marker for prognosis in various cancers. Minerva Medica, 2017, 108, 477-479.	0.9	2
70	SARS-CoV-2 is less likely to infect aquatic food animals: sequence and phylogeny analysis of ACE2 in mammals and fish. Molecular Biomedicine, 2020, 1, 13.	4.4	2
71	CRISPR signal conductor 2.0 for redirecting cellular information flow. Cell Discovery, 2022, 8, 26.	6.7	2
72	Characterization of the Transcriptome of Hair Cell Regeneration in the Neonatal Mouse Utricle. Cellular Physiology and Biochemistry, 2018, 51, 1437-1447.	1.6	1

#	Article	IF	Citations
73	Artificial small RNA for sequence specific cleavage of target RNA through RNase III endonuclease Dicer. Oncotarget, 2016, 7, 54549-54554.	1.8	1
74	Engineering Cellular Signal Sensors based on CRISPR-sgRNA Reconstruction Approaches. International Journal of Biological Sciences, 2020, 16, 1441-1449.	6.4	0
75	Editorial: Engineering Signal Sensors Based on Reprogrammed CRISPR Technologies. Frontiers in Molecular Biosciences, 2021, 8, 742961.	3.5	0